Black Diamond Therapeutics
BDTX
BDTX
74 hedge funds and large institutions have $209M invested in Black Diamond Therapeutics in 2023 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
48% more funds holding
Funds holding: 50 → 74 (+24)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
Holders
74
Holding in Top 10
2
Calls
$3.11M
Puts
$398K
Top Buyers
| 1 | +$5.6M | |
| 2 | +$4.08M | |
| 3 | +$3.68M | |
| 4 |
RI
RTW Investments
New York
|
+$3.47M |
| 5 |
JP Morgan Chase
New York
|
+$2.2M |
Top Sellers
| 1 | -$2.25M | |
| 2 | -$866K | |
| 3 | -$333K | |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$274K |
| 5 |
NM
Newtyn Management
New York
|
-$218K |